Wogonin ameliorates hyperglycemia and dyslipidemia via PPARα activation in db/db mice

Eun Jung Bak, Jinmoon Kim, Yun Hui Choi, Ji Hye Kim, Dong Eun Lee, Gye Hyeong Woo, JeongHeon Cha, Yun Jung Yoo

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Background & aims: Wogonin is a flavonoid extracted from the root of Scutellaria baicalensis Gerogi. We evaluated the therapeutic effects of wogonin using db/db mice. Methods: Mice received wogonin or vehicle by oral gavage for 2 weeks. Blood glucose, insulin, and cholesterol levels were measured, and liver morphology was observed with histopathological analysis. The mRNA expression levels of PPARα, PPARγ, and adiponectin in the liver and white adipose tissue (WAT) were determined by real-time PCR. Immunoblotting for AMPK and PPARγ, and adipocyte differentiation were investigated invitro using 3T3-L1 cells. A luciferase assay was used to measure PPARα and PPARγ binding activity. Results: The wogonin group showed decreased weight gain without a change in food intake and improved glucose tolerance. Serum insulin and cholesterol levels in the wogonin group were significantly decreased compared to those in the control group. The wogonin group also showed less accumulation of lipid droplets and glycogen in the liver. PPARα and PPARγ expression levels in the liver and WAT and adiponectin expression level in WAT in the wogonin group were higher than those in the control group. In 3T3-L1 cells, wogonin was shown to stimulate AMPK activation in a dose-dependent manner. The presence of wogonin did not affect adipocyte differentiation or PPARγ protein level during adipogenesis. Notably, wogonin enhanced PPARα but not PPARγ transactivation. Conclusions: These indicate that wogonin may have beneficial effects on glucose and lipid metabolism related to enhanced PPARα and adiponectin expression via AMPK activation. Importantly, wogonin did not cause deleterious effects, such as weight gain and fatty liver. Wogonin might be a useful therapeutic agent to treat type 2 diabetes.

Original languageEnglish
Pages (from-to)156-163
Number of pages8
JournalClinical Nutrition
Volume33
Issue number1
DOIs
Publication statusPublished - 2014 Feb 1

Fingerprint

Peroxisome Proliferator-Activated Receptors
Dyslipidemias
Hyperglycemia
White Adipose Tissue
AMP-Activated Protein Kinases
Adiponectin
3T3-L1 Cells
Adipocytes
wogonin
Weight Gain
Liver
Cholesterol
Scutellaria baicalensis
Insulin
Glucose
Adipogenesis
Control Groups
Liver Glycogen
Therapeutic Uses
Fatty Liver

All Science Journal Classification (ASJC) codes

  • Nutrition and Dietetics
  • Critical Care and Intensive Care Medicine

Cite this

Bak, E. J., Kim, J., Choi, Y. H., Kim, J. H., Lee, D. E., Woo, G. H., ... Yoo, Y. J. (2014). Wogonin ameliorates hyperglycemia and dyslipidemia via PPARα activation in db/db mice. Clinical Nutrition, 33(1), 156-163. https://doi.org/10.1016/j.clnu.2013.03.013
Bak, Eun Jung ; Kim, Jinmoon ; Choi, Yun Hui ; Kim, Ji Hye ; Lee, Dong Eun ; Woo, Gye Hyeong ; Cha, JeongHeon ; Yoo, Yun Jung. / Wogonin ameliorates hyperglycemia and dyslipidemia via PPARα activation in db/db mice. In: Clinical Nutrition. 2014 ; Vol. 33, No. 1. pp. 156-163.
@article{7b91d20097e143f2ba8faf347ab039f1,
title = "Wogonin ameliorates hyperglycemia and dyslipidemia via PPARα activation in db/db mice",
abstract = "Background & aims: Wogonin is a flavonoid extracted from the root of Scutellaria baicalensis Gerogi. We evaluated the therapeutic effects of wogonin using db/db mice. Methods: Mice received wogonin or vehicle by oral gavage for 2 weeks. Blood glucose, insulin, and cholesterol levels were measured, and liver morphology was observed with histopathological analysis. The mRNA expression levels of PPARα, PPARγ, and adiponectin in the liver and white adipose tissue (WAT) were determined by real-time PCR. Immunoblotting for AMPK and PPARγ, and adipocyte differentiation were investigated invitro using 3T3-L1 cells. A luciferase assay was used to measure PPARα and PPARγ binding activity. Results: The wogonin group showed decreased weight gain without a change in food intake and improved glucose tolerance. Serum insulin and cholesterol levels in the wogonin group were significantly decreased compared to those in the control group. The wogonin group also showed less accumulation of lipid droplets and glycogen in the liver. PPARα and PPARγ expression levels in the liver and WAT and adiponectin expression level in WAT in the wogonin group were higher than those in the control group. In 3T3-L1 cells, wogonin was shown to stimulate AMPK activation in a dose-dependent manner. The presence of wogonin did not affect adipocyte differentiation or PPARγ protein level during adipogenesis. Notably, wogonin enhanced PPARα but not PPARγ transactivation. Conclusions: These indicate that wogonin may have beneficial effects on glucose and lipid metabolism related to enhanced PPARα and adiponectin expression via AMPK activation. Importantly, wogonin did not cause deleterious effects, such as weight gain and fatty liver. Wogonin might be a useful therapeutic agent to treat type 2 diabetes.",
author = "Bak, {Eun Jung} and Jinmoon Kim and Choi, {Yun Hui} and Kim, {Ji Hye} and Lee, {Dong Eun} and Woo, {Gye Hyeong} and JeongHeon Cha and Yoo, {Yun Jung}",
year = "2014",
month = "2",
day = "1",
doi = "10.1016/j.clnu.2013.03.013",
language = "English",
volume = "33",
pages = "156--163",
journal = "Clinical Nutrition",
issn = "0261-5614",
publisher = "Churchill Livingstone",
number = "1",

}

Bak, EJ, Kim, J, Choi, YH, Kim, JH, Lee, DE, Woo, GH, Cha, J & Yoo, YJ 2014, 'Wogonin ameliorates hyperglycemia and dyslipidemia via PPARα activation in db/db mice', Clinical Nutrition, vol. 33, no. 1, pp. 156-163. https://doi.org/10.1016/j.clnu.2013.03.013

Wogonin ameliorates hyperglycemia and dyslipidemia via PPARα activation in db/db mice. / Bak, Eun Jung; Kim, Jinmoon; Choi, Yun Hui; Kim, Ji Hye; Lee, Dong Eun; Woo, Gye Hyeong; Cha, JeongHeon; Yoo, Yun Jung.

In: Clinical Nutrition, Vol. 33, No. 1, 01.02.2014, p. 156-163.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Wogonin ameliorates hyperglycemia and dyslipidemia via PPARα activation in db/db mice

AU - Bak, Eun Jung

AU - Kim, Jinmoon

AU - Choi, Yun Hui

AU - Kim, Ji Hye

AU - Lee, Dong Eun

AU - Woo, Gye Hyeong

AU - Cha, JeongHeon

AU - Yoo, Yun Jung

PY - 2014/2/1

Y1 - 2014/2/1

N2 - Background & aims: Wogonin is a flavonoid extracted from the root of Scutellaria baicalensis Gerogi. We evaluated the therapeutic effects of wogonin using db/db mice. Methods: Mice received wogonin or vehicle by oral gavage for 2 weeks. Blood glucose, insulin, and cholesterol levels were measured, and liver morphology was observed with histopathological analysis. The mRNA expression levels of PPARα, PPARγ, and adiponectin in the liver and white adipose tissue (WAT) were determined by real-time PCR. Immunoblotting for AMPK and PPARγ, and adipocyte differentiation were investigated invitro using 3T3-L1 cells. A luciferase assay was used to measure PPARα and PPARγ binding activity. Results: The wogonin group showed decreased weight gain without a change in food intake and improved glucose tolerance. Serum insulin and cholesterol levels in the wogonin group were significantly decreased compared to those in the control group. The wogonin group also showed less accumulation of lipid droplets and glycogen in the liver. PPARα and PPARγ expression levels in the liver and WAT and adiponectin expression level in WAT in the wogonin group were higher than those in the control group. In 3T3-L1 cells, wogonin was shown to stimulate AMPK activation in a dose-dependent manner. The presence of wogonin did not affect adipocyte differentiation or PPARγ protein level during adipogenesis. Notably, wogonin enhanced PPARα but not PPARγ transactivation. Conclusions: These indicate that wogonin may have beneficial effects on glucose and lipid metabolism related to enhanced PPARα and adiponectin expression via AMPK activation. Importantly, wogonin did not cause deleterious effects, such as weight gain and fatty liver. Wogonin might be a useful therapeutic agent to treat type 2 diabetes.

AB - Background & aims: Wogonin is a flavonoid extracted from the root of Scutellaria baicalensis Gerogi. We evaluated the therapeutic effects of wogonin using db/db mice. Methods: Mice received wogonin or vehicle by oral gavage for 2 weeks. Blood glucose, insulin, and cholesterol levels were measured, and liver morphology was observed with histopathological analysis. The mRNA expression levels of PPARα, PPARγ, and adiponectin in the liver and white adipose tissue (WAT) were determined by real-time PCR. Immunoblotting for AMPK and PPARγ, and adipocyte differentiation were investigated invitro using 3T3-L1 cells. A luciferase assay was used to measure PPARα and PPARγ binding activity. Results: The wogonin group showed decreased weight gain without a change in food intake and improved glucose tolerance. Serum insulin and cholesterol levels in the wogonin group were significantly decreased compared to those in the control group. The wogonin group also showed less accumulation of lipid droplets and glycogen in the liver. PPARα and PPARγ expression levels in the liver and WAT and adiponectin expression level in WAT in the wogonin group were higher than those in the control group. In 3T3-L1 cells, wogonin was shown to stimulate AMPK activation in a dose-dependent manner. The presence of wogonin did not affect adipocyte differentiation or PPARγ protein level during adipogenesis. Notably, wogonin enhanced PPARα but not PPARγ transactivation. Conclusions: These indicate that wogonin may have beneficial effects on glucose and lipid metabolism related to enhanced PPARα and adiponectin expression via AMPK activation. Importantly, wogonin did not cause deleterious effects, such as weight gain and fatty liver. Wogonin might be a useful therapeutic agent to treat type 2 diabetes.

UR - http://www.scopus.com/inward/record.url?scp=84892552728&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84892552728&partnerID=8YFLogxK

U2 - 10.1016/j.clnu.2013.03.013

DO - 10.1016/j.clnu.2013.03.013

M3 - Article

VL - 33

SP - 156

EP - 163

JO - Clinical Nutrition

JF - Clinical Nutrition

SN - 0261-5614

IS - 1

ER -